YMAB
Y-mAbs Therapeutics
YMAB
YMAB
Delisted
YMAB was delisted on the 15th of September, 2025.
95 hedge funds and large institutions have $294M invested in Y-mAbs Therapeutics in 2024 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 35 increasing their positions, 34 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
95
Holders Change
–
Holders Change %
0%
% of All Funds
1.38%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
17
Increased
35
Reduced
34
Closed
16
Calls
$329K
Puts
$4K
Net Calls
+$325K
Net Calls Change
+$385K
Top Buyers
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$19.8M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$17.5M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$1.73M |
| 4 |
BlackRock
New York
|
+$984K |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$930K |
Top Sellers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$14.1M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$3.37M |
| 3 |
Goldman Sachs
New York
|
-$2.74M |
| 4 |
Los Angeles Capital Management
Los Angeles,
California
|
-$2.07M |
| 5 |
Nuveen Asset Management
Chicago,
Illinois
|
-$1.88M |
